Bruker (BRKR) Expected to Announce Quarterly Earnings on Thursday

Bruker (NASDAQ:BRKR) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $0.65 per share and revenue of $964.6130 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 13, 2026 at 12:30 PM ET.

Bruker (NASDAQ:BRKR) last released its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The company had revenue of $860.50 million for the quarter, compared to the consensus estimate of $847.40 million. During the same period in the prior year, the company posted $0.60 EPS. The company’s revenue was down .5% compared to the same quarter last year. On average, analysts expect Bruker to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Bruker Stock Down 0.2%

Shares of NASDAQ:BRKR opened at $42.56 on Thursday. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91. The stock has a market cap of $6.47 billion, a price-to-earnings ratio of -266.00, a P/E/G ratio of 5.61 and a beta of 1.19. The company has a 50 day moving average of $47.98 and a 200-day moving average of $40.48. Bruker has a one year low of $28.53 and a one year high of $57.92.

Analyst Upgrades and Downgrades

BRKR has been the subject of a number of analyst reports. Barclays lifted their price objective on Bruker from $45.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Guggenheim increased their target price on shares of Bruker from $53.00 to $58.00 and gave the stock a “buy” rating in a report on Monday, January 26th. UBS Group boosted their price target on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Bank of America raised their price objective on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Rothschild & Co Redburn started coverage on Bruker in a report on Thursday, November 20th. They issued a “buy” rating and a $60.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bruker has an average rating of “Moderate Buy” and an average target price of $53.71.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at $7,064,365. This trade represents a 5.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 27.30% of the company’s stock.

Institutional Investors Weigh In On Bruker

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Allworth Financial LP grew its stake in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares in the last quarter. Armistice Capital LLC bought a new position in Bruker in the third quarter valued at $321,000. Dark Forest Capital Management LP increased its stake in Bruker by 256.0% in the 3rd quarter. Dark Forest Capital Management LP now owns 71,779 shares of the medical research company’s stock valued at $2,332,000 after buying an additional 51,614 shares during the last quarter. XTX Topco Ltd bought a new stake in Bruker during the 3rd quarter worth about $589,000. Finally, Voloridge Investment Management LLC increased its position in shares of Bruker by 408.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 831,834 shares of the medical research company’s stock worth $27,026,000 after purchasing an additional 668,078 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.